Neoadjuvant chemotherapy in breast cancers

Women's Health

Volumn 12, Issue 5, 2016, Pages 480-491

  Masood, Shahla ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

Author keywords

Breast cancer; Breast pathology report; Neoadjuvant chemotherapy

Indexed keywords

BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CLINICAL OUTCOME; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; LUMPECTOMY; NEOADJUVANT CHEMOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENTINEL LYMPH NODE BIOPSY; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR RECURRENCE; TUMOR VOLUME; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; MASTECTOMY; METABOLISM; NEOADJUVANT THERAPY; PARTIAL MASTECTOMY; PATHOLOGY; PROCEDURES; PROGNOSIS;

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 85015297384     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.1177/1745505716677139     Document Type: Review

References (63)

1. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 1999; 17(2): 460-469.
2. Smith IE and Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001; 2: 561-570.
3. Kaufmann M, Von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21(13): 2600-2608.
4. Mauri D, Pavlidis N and Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
5. Mieog J, Van der Hage JA and Van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007; 2: CD005002
6. Liu SV, Melstrom L, Yao K, et al. Neoadjuvant therapy for breast cancer. J Surg Oncol 2010; 101: 283-291.
7. Shin HC, Han W, Moon HG, et al. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol 2013; 20: 2582-2589.
8. Mieog JS, Van der Hage JA and Van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007; 94(10): 1189-1200.
9. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
10. Vugts G, Maaskant-Braat AJG, Nieuwenhuijzen GAP, et al. Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer. A population based study. Breast J 2016; 22(3): 316-321.
11. Sahoo S, Dabbs DJ and Bhargava R. Pathology of neoadjuvant response of breast carcinoma. In: Dabbs DJ (ed.) Breast pathology (vol. 1). Philadelphia, PA: Elsevier Saunders, 2012, pp. 519-535.
12. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95: 681-695.
13. Precht IM, Lowe KA, Atwood M, et al. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010; 16: 362-368.
14. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011; 117(9): 1819-1826.
15. Van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer 2009; 45: 3124-3130.
16. Schwartz GF, Tannenbaum JE, Jernigan AM, et al. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 2010; 116: 1243-1251.
17. Kaufmann M, Von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18(12): 1927-1934.
18. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172.
19. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-2581.
20. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007; 25: 2650-2655.
21. Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
22. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 Trial (CALGB 150007/150012). Breast Cancer Res Treat 2012; 132: 1049-1062.
23. Von Minckwitz G, Untch M, Muesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125(1): 145-156.
24. Gluck S, de Snoo F, Stork-Sloots L, et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 139(3): 759-767. 2013.
25. Whitworth P, Stork-Sloots L, De Snoo FA, et al. Chemo sensitivity predicted by bluePrint 80-gene functional subtype and MammaPrint in the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol 2014; 21(10): 3261-3267.
26. Romero A, Prat A, Garcia-Saenz JA, et al. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection. Clin Transl Oncol 2012; 16(4): 386-394.
27. Turner N, Biganzoli L, Malorni L, et al. Adjuvant chemotherapy: which patient? What regimen? Am Soc Clin Oncol Educ Book 2013; 4: 3-8.
28. Balmativola D, Marchio C, Maule M, et al. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat 2014; 148: 511-523.
29. Delpech Y, Coutant C, Hsu L, et al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 2013; 108(2): 285-291.
30. Marchio C and Sapino A. The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr 2011; 43: 86-90.
31. Pu RT, Schott AF, Sturtz DE, et al. Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 2005; 29(3): 354-358.
32. Sahoo S and Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 2009; 133(4): 633-642.
33. Cox CE, Cox JM, White LB, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol 2006; 13(4): 483-490.
34. Pierga JY, Mouret E, Laurence V, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response. Eur J Cancer 2003; 39(8): 1089-1096.
35. Keune JD, Jeffe DB, Schootman M, et al. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg 2010; 199: 477-484.
36. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005; 184(6): 1774-1781.
37. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004; 14: 1371-1379.
38. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112(1): 17-26.
39. Partridge SC, Vanantwerp RK, Doot RK, et al. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 2010; 32(5): 1124-1131.
40. Sharkey FE, Addington SL, Fowler LJ, et al. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 1996; 9(9): 893-900.
41. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
42. Cleator SJ, Makris A, Ashley SE, et al. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005; 16(2): 267-272.
43. Marchio C, Maletta F, Annaratone L, et al. The perfect pathology report after neoadjuvant therapy. J Natl Cancer Inst Monogr 2015; 2015(51): 47-50.
44. Rajan R, Poniecka A, Smith TL, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004; 100(7): 1365-1373.
45. Schneeweiss A, Katretchko J, Sinn HP, et al. Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anticancer Drugs 2004; 15(2): 127-135.
46. Haffty BG, Perrotta PL, Ward BE, et al. Conservatively treated breast cancer: outcome by histologic type. Breast J 1997; 3: 7
47. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13(8): 2329-2334.
48. Mamounas E, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30(32): 3960-3966.
49. Carey LA, Metzger R, Dees FC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97: 1137-1142.
50. Hennessy BT, Hortobagyi GN, Rousier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary lymph node metastases following primary chemotherapy. J Clin Oncol 2005; 23(36): 9304-9311.
51. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predict survival after neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010; 116: 1431-1439.
52. Van de Ven S, Smit VT, Dekker TJ, et al. Discordances in ER, PR, and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011; 37: 422-430.
53. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94: 2169-2173.
54. Tacca O, Penault-Llorca F, Abrial C, et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2007; 12: 636-643.
55. Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008; 61: 569-577.
56. Jones RL, Salter J, A’Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53-68.
57. Decensi A, Guerrieri-Gonzaga A, Gandini S, et al. Prognostic significance of Ki-67 labeling index after shortterm presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2011; 22: 582-587.
58. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25(28): 4414-4422.
59. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 12(5): 320-327.
60. Von Minckwitz G, Kaufmann M, Kuemmel S, et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol 2011; 29: 1028.
61. Provenzano E, Vallier A-L, Champ R, et al. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer 2013; 108: 866-872.
62. Peintinger F, Sinn B, Hatzis C, et al. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol 2015; 28: 913-920.
63. College of American Pathologists. Protocol for the examination of specimens from patients with invasive carcinoma of the breast, http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/BreastInvasive_12protocol_3100.pdf (2012, accessed 30 October 2014).